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Our previous studies have demonstrated functional protein−protein interactions
between cytochrome P450 (CYP) 3A and UDP-glucuronosyltransferase (UGT).
However, the role of carbohydrate chains of UGTs in the interaction with CYP is not
well understood. To address this issue, we examined whether CYP3A1 modulates the
function of UGT2B3 which lacks potential glycosylation sites. We also examined whether
the introduction of N-glycosylation to UGT2B3 affects CYP3A-dependent modulation
of UGT function. To introduce a potential glycosylation site into UGT2B3, Ser 316 of
UGT2B3 was substituted with Asn by site-directed mutagenesis. A baculovirus-Sf-9
cell system for expressing CYP3A1 and UGT2B3/UGT2B3(S316N) was established
using a Bac-to-Bac system. Glycosylation of UGT2B3(S316N) was demonstrated in this
expression system. The microsomal activity of recombinant UGT was determined using
4-methylumbelliferone as a substrate. The effect of CYP3A1 co-expression on UGT
function was examined by comparing the kinetic profiles between single (UGT alone) and
double expression (UGT plus CYP) systems. The kinetics of the two expression systems
fitted a Michaelis−Menten equation. When the 4-MU concentration was varied, co-
expression of CYP3A1 lowered the Vmax of UGT2B3-mediated conjugation. Conversely,
for UGT2B3(S316N), the Vmax in the dual expression system was higher than that in
the single expression system. The data obtained demonstrate that the introduction of
N-glycosylation to UGT2B3 alters its sensitivity to CYP3A1-dependent modulation while
CYP3A1 enhanced UGT2B3(S316N) activity, and wild-type UGT2B3 was suppressed
by CYP3A1. These data suggest that N-glycosylation of UGT is one of the determinants
regulating the interaction between CYP3A and UGT.
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INTRODUCTION
The potential for drug metabolism varies from one individual
to another. Therefore, drug metabolism capacity is a factor
determining whether a drug produces pharmacological or
adverse effects. Drug metabolism is classified into phase 1 and
phase 2 reactions. The major reaction of phase 1 is oxidation
in which cytochrome P450 (CYP) plays a key role (Guengerich
and Rendic, 2010). Of all the enzymes including phase 2, UDP-
glucuronosyltransferase (UGT) is mediating conjugation with
glucuronic acid supplied from a cofactor (UDP-glucuronic acid,
UDPGA) (Rowland et al., 2013). CYP and UGT are bound to the
endoplasmic reticulum membrane, and their catalytic domains
are localized in the cytosolic and luminal sides, respectively
(Shepherd et al., 1989; Yamazaki et al., 1993). These enzymes
have long been considered to work separately. However, we
have shown that several UGTs can be trapped by a CYP1A1-
immobilized affinity column (Taura et al., 2000). Moreover,
our previous studies have shown that interaction between
CYP3A4 and UGT2B7 alters the regio-selectivity of UGT2B7-
catalyzed morphine glucuronidation (Takeda et al., 2005, 2009).
Furthermore, CYP3A4 alters the function of UGT1A subfamily
isoforms in an isoform and allelic variant specific fashion (Ishii
et al., 2014). Rat UGTs are efficiently co-immunoprecipitated
with anti-CYP3A antibody and the CYP3A-UGT complex is
catalytically active for 4-methylumbelliferone glucuronidation
(Ishii et al., 2007). Although the mechanisms of the interaction
between CYP3A and UGT have not been clarified, the J-helix
region of CYP3A4 is a candidate region involved in the
interaction with UGT2B7 (Takeda et al., 2009). The domain(s)
of UGT2B7 involved in the interaction with CYP3A4 has also
been reported (Miyauchi et al., 2015). It is suggested that the
hydrophobic regions at both the carboxyl terminal and luminal
anchoring segment of UGT2B7 are crucial. However, further
details about the interaction remain to be clarified.
Many UGTs have consensus sequences for N-glycosylation
(Mackenzie, 1990a,b; Barbier et al., 2000; Nakajima et al.,
2010; Nagaoka et al., 2012). The sequence can be generalized
as NX(S/T), where X is any amino acid except proline, and
approximately 70-90% of this sequence is glycosylated at its
asparagine (N) residue (Gavel and von Heijne, 1990). Earlier
studies have reported that N-glycosylation affects the enzyme
activity of UGTs (Mackenzie, 1990a,b; Barbier et al., 2000;
Nakajima et al., 2010; Nagaoka et al., 2012). We have reported
that CYP3A4 interacts with UGT1A1, 1A6, 1A7, and 2B7 (Takeda
et al., 2005; Ishii et al., 2014). All of these UGT isoforms
possess potential N-glycosylation sites. However, the role of N-
glycosylation of UGT in the interaction with CYP3A is unknown.
Although the inhibition of N-glycosylation reduces UGT1A9
activity, deglycosylation of the mature form (N-glycosylated
form) did not affect its catalytic properties (Nakajima et al.,
2010). Thus, N-glycosylation has been suggested to be important
for the protein folding of UGT. However, multiple mutations
of the three N-glycosylation sites on UGT2B7 have different
effects on substrate specificities (Nagaoka et al., 2012). Because
of the important roles of N-glycosylation in UGT folding and
function, we hypothesized that the N-glycosylation of UGT
affects the interaction between CYP3A and UGT. To address this
issue, we focused on rat UGT2B3 (Mackenzie, 1987) which does
not possess potential glycosylation sites. We examined whether
CYP3A1 modulates UGT2B3 and whether the introduction
of N-glycosylation to UGT2B3 affects the CYP3A-dependent
modulation of the UGT function.
MATERIALS AND METHODS
Materials
4-Methylumbelliferone (4-MU) and alamethicin were purchased
from Sigma−Aldrich (St. Louis, MO, USA). UDP-Glucuronic
acid (UDPGA) trisodium salt and 4-MU-β-D-glucuronide were
obtained from Nakalai Tesque (Kyoto, Japan). Endoglycosidase
H (EndoH) was purchased from New England Biolabos (Beverly,
MA, USA). All other reagents were of the highest grade
commercially available.
Animals
Animal experiments in this study were conducted following the
approval of the Ethics Committee for Animal Experiments of
Kyushu University. Male Wistar rats (7 weeks-old) were obtained
from Charles River Japan (Tokyo, Japan) and were maintained
for one week with free access to water and a suitable diet under
a 7 a.m. to 7 p.m. light/dark cycle. For isolation of total RNA,
liver tissue was quickly cut into small fragments, immediately
immersed in liquid nitrogen, and stored at−80◦C until required.
Expression System
Baculovirus for expressing CYP3A1 and UGT2B3 in Sf-9 cells
was prepared using a Bac-to-Bac system (Invitrogen). CYP3A1
cDNA was subcloned from P91023(B) (Nagata et al., 1999)
into pFastBac1 vector at an EcoRI site. The sequencing reaction
was carried out using a Big Dye R© Terminator v3.1 Cycle
Sequencing Kit (Life Technologies). Then, cDNA sequences were
confirmed by an ABI 3130xl Genetic Analyzer. CYP3A1 has two
synonymous and one non-synonymous nucleotide substitutions:
C1035G, G1074A, and T1055A, respectively, when compared
with the database (Gonzalez et al., 1985; GenBank accession
M10161). T1055A causes an amino acid substitution, M352K,
and this CYP3A1 is known to be catalytically active (Nagata et al.,
1999). It was used as the CYP3A1 in this study.
UGT2B3 cDNA was amplified from the total RNA of Wistar
rat liver by a reverse transcription-polymerase chain reaction
(RT-PCR), and cloned into pFastBac1. Isolation of total RNA
and the RT-reaction were carried out by a method previously
reported (Mutoh et al., 2006). To amplify the cDNA, nested
PCR with two primer sets was used. The primer set for the
first round PCR was UGT2B3(-20,-1)F1, 5′- TAA GGA TTT
TGA TTT TTA AG-3′ and UGT2B3(1647,1628)R1, 5′-CAT AAA
T TA GAA TGA GGC TG-3′. The primer set for the second
round PCR was PstI-UGT2B3(-5,15)F2, 5′-AAC TGC AGT TAA
GAT GCC TGG GAA GTG G-3′, and PstI-UGT2B3(1615,
1596)R2, 5′-AAC TGC AGT GTA GTG CAT TGT AA ATG AG-
3′ with restriction sites (PstI) underlined. The PCR was carried
out with LA-Taq DNA polymerase (TaKaRa Bio, Kyoto) using
Frontiers in Pharmacology | www.frontiersin.org 2 November 2016 | Volume 7 | Article 427
fphar-07-00427 November 14, 2016 Time: 15:9 # 3
Nakamura et al. CYP3A1-Dependent Alteration of UGT2B3 Activity
the manufacturer’s recommended protocol with the following
components: 1xLA-Taq buffer, 2 mM MgCl2, 2.5 mM each dNTP,
the primers F1 and R1 (5 µM each) and the cDNA in 100 µL
(first round PCR). The amplification was carried out using
the PROGRAM TEMP CONTROL SYSTEM PC-800 (ASTEC,
Fukuoka, Japan) with 94◦C, 4 min-(94◦C, 1 min, 50◦C, 1 min,
72◦C, 2 min)×30 cycles-72◦C, 20 min –4◦C, ∞. The second
round PCR was carried out as above but using primers F2 and R2.
The resulting PCR products were restricted with PstI and cloned
into pFastBac1. The sequence was confirmed by DNA sequencing
as described above. UGT2B3 has a non-synonymous nucleotide
substitution, T1498A, which causes a single amino-acid change,
S500T. We used this as a wild-type UGT2B3 in this study.
Escherichia coli DH10Bac was transformed either with
pFastBac1 plasmid carrying UGT2B3 or CYP3A1 cDNA
to prepare recombinant bacmid DNA. Production and
amplification of recombinant baculovirus and expression of
recombinant proteins in Sf-9 cells were carried out according to
the method described previously (Ishii et al., 2014).
The Introduction of a Potential
N-Glycosylation Site into UGT2B3
UGT2B3 exhibits 83% identity to UGT2B2 (Mackenzie, 1986) in
amino acid sequences. The Asn 316 of UGT2B2 is a potential site
for glycosylation. Therefore, the Ser 316 of UGT2B3 was replaced
with Asn by site-directed mutagenesis (SDM), and an expression
system for the UGT2B3(S316N) mutant was constructed in a
similar way as described above. The primers for the SDM were
designed by Quick Change Primer Design (Agilent Technology).
The primers used were UGT2B3(931, 964)(947G→A)SDM-F, 5′-
GGG TCA ATG GTC AGC AAC ATG ACA GAA GAA AAG
G-3′ and UGT2B3(964, 931)(947C→T)SDM-R, 5′-CCT TTT
CTT CTG TCA TGT TGC TGA CCA TTG ACC C-3′. The
procedures were carried out according to the manufacturer’s
recommendations. The introduction of the mutation at the
appropriate position and the absence of other unwanted
mutations were confirmed by DNA sequencing.
Kinetic Analysis
The kinetic analysis was performed using 100 µg microsomal
protein. The amount of microsomal protein used was unified by
adding control baculosomes. The activity of UGT2B3-catalyzed
glucuronidation was determined by high-performance liquid
chromatography (HPLC) with 4-MU as a substrate (Hanioka
et al., 2001). The microsomes and alamethicin were mixed and
preincubated for 30 min on ice. The assay was started by adding
UDPGA and incubation was performed for 60 min at 37◦C.
The reaction was stopped with 100 µL 1 M trichloroacetic acid
(TCA). After chilling on ice for 30 min, the incubation mixture
was centrifuged (15,000 rpm, 4◦C, 10 min). The supernatant
containing the 4-MU glucuronide formed was analyzed by HPLC
with a fluorescence detector (Ex 315 nm, Em 375 nm).
Data Analysis
The kinetics fitted a Michaelis−Menten equation, and the
kinetic parameters were calculated using GraphPad Prism
software (GraphPad Software Inc., San Diego, CA, USA). The
statistical difference in kinetic parameters between UGT2B3
single expression and UGT2B3-CYP3A1 dual expression was
evaluated by repeating the extra sum-of-squares F test.
Immunoblotting
Proteins were determined by the method of Lowry et al.
(1951) with bovine serum albumin as a standard. SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) was performed
according to Laemmli (1970). Proteins separated by SDS-PAGE
were electroblotted to a polyviniliden difluoride membrane.
UGT2B3 and UGT2B3(S316N) were detected by a goat
anti-mouse low-pI form UGT antibody (Mackenzie et al.,
1984). CYP3A1 was detected by rabbit anti-CYP3A2 antibody
(Nagata et al., 1990). Immunochemical detection was conducted
either with horseradish peroxidase (HRP)-conjugated secondary
antibodies, HRP-rabbit anti-goat IgG (MP Biomedicals, Santa
Ana, CA, USA), or HRP-donkey anti-rabbit IgG (GE Healthcare,
Piscataway, NJ, USA). These were diluted 10,000- and 40,000-fold
before use, respectively. Clarity Western ECL Substrate (Bio-Rad,
Hercules, CA, USA) was used as the substrate of HRP, and the
chemiluminescence emitted was analyzed by a ChemiDoc MP
System (Bio-Rad).
His-Tag Pull-Down Assay
Introduction of hemagglutinin (HA)-tag at the carboxyl terminus
of UGT2B3 was carried out by a two-step PCR. At the first
step, primer HA(21,1)-UGT2B3(1590,1573)R, 5′-ATC TGG AAC
ATC GTA TGG GTA CTC ATT CTT CAT TTT CTT-3′ and
primer F2 were used. The PCR reaction was basically the same
as that above except that pFastBac1-UGT2B3 was the template.
In the second step, PstI-TCA-HA(27,1)R, 5′-AAC TGC AGT
CAA GGG TAA TCT GGA ACA TCG TAT GGG TA-3′ and
primer F2 were used (Underline, PstI site). In the second step,
the PCR products of the first step were used as a template.
The PCR products were restricted with PstI and cloned into
pFastBac1. To construct HA-tagged UGT2B3(S316N), an SDM
described above was carried out with pFastBac1-UGT2B3-
HA. To construct hexa-histidine (His)6-tagged CYP3A1, PCR
was carried out with the following primers: NotI-CYP3A1
(-4,16)F, 5′-ATA AGA ATG CGG CCG CAG GGA TGG ACC
TGC TTT CAG-3′ and XhoI-CYP3A1-Histag(1510,1494)R, 5′-
CCG CTC GAG TCA GTG ATG GTG ATG GTG ATG
TGA TCC AGT TAT GAT TTC A-3′ (Underlines: NotI and
XhoI sites, respectively). The PCR products were purified and
restricted with NotI and XhoI and then subcloned into pFastBac1
restricted with the same enzymes. Their recombinant baculovirus
was prepared as described above. Sf-9 cells were transfected
with the recombinant virus for either CYP3A1-(His)6 and/or
UGT2B3-HA/UGT2B3(S316N). The resulting microsomes were
solubilized with sodium cholate and the pulled down assays
were carried out as described previously (Miyauchi et al.,
2015).
Modeling of the Structure of the UGTs
The models were constructed using Phyre2 (Protein
Homology/Analogy Recognition Engine V 2.0) web server,
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http://www.sbg.bio.ic.ac.uk/phyre2/html/ (Kelley et al., 2015)
with UGT2B7 (amino acid residue from 285 to 450) as a template
(Miley et al., 2007). Although the program is designed for
prediction using multiple templates, only UGT2B7 was selected
as a template in this case.
RESULTS
Expression of UGT2B3 and the
Glycosylation Mutant, UGT2B3(S316N)
UGT2B3 was expressed in Sf-9 cells, and the protein band in
the 50−60 kDa molecular mass range that was immunoreactive
toward anti-mouse low pI form UGT antibody and was
absent in control microsomes was judged to be UGT2B3
(Figure 1A). To introduce an N-glycosylated sugar chain to
UGT2B3, we referred to UGT2B2 (Mackenzie, 1986) which has
a potential N-glycosylation site and exhibits high similarity to
UGT2B3 in primary sequence. Then, the Ser316 of UGT2B3
was substituted to Asn to establish an expression system
for UGT2B3(S316N). The immune-reactive band with higher
molecular mass and absent in control microsomes was judged
to be UGT2B3(S316N)(Figure 1A). Thus, the molecular mass
was increased by the introduction of a potential glycosylation
site suggesting newly introduced N-glycosylation. This was
also supported by a reduction in size after EndoH-treatment
(Figure 1A).
Effect of Co-Expression of CYP3A1 on
UGT2B3- and UGT2B3(S316N)-Catalyzed
Glucuronidation
CYP3A1 was co-expressed in Sf-9 cells with UGT2B3 or
UGT2B3(S316N). Sf-9 cells, the microsomes of which express
UGT2B3 or UGT2B3(S316N) having a comparable band
intensity to that in the single expression system, were selected
and subjected to further investigation of their enzymatic
properties (Figures 1B–E). The amount of UGT2B3 and
microsomal protein used for the assay was also unified
between the single and dual expression systems. For this,
we rendered the protein level uniform with baculosomes
obtained from Sf-9 cells infected with control baculovirus.
When CYP3A1 was expressed together with UGT2B3, the
Vmax of UGT2B3-catalyzed 4-MU glucuronidation was
significantly decreased (Figure 2; Table 1). The kinetic
profiles for both the single and double expression could be
fitted to a Michaelis−Menten equation. When the 4-MU
concentration was varied, the Vmax was reduced significantly
while the Km was comparable (Table 1). Furthermore, the
same was also true for the kinetics by varying the UDPGA
concentration (Figure 3; Table 1). The Vmax was lowered
by CYP3A1 cotransfection while the Km for UDPGA was
comparable. Therefore, CYP3A1 suppressed the activity of
UGT2B3 which lacks potential glycosylation sites. However,
when CYP3A1 was expressed together with UGT2B3(S316N),
the Vmax of UGT2B3(S316N)-catalyzed 4-MU glucuronidation
was significantly increased (Figure 3; Table 2). The kinetic
FIGURE 1 | Immunoblots of the expression of UGT2B3,
UGT2B3(S316N), and CYP3A1 in Sf-9 cells. To obtain microsomes
simultaneously expressing CYP3A1 and UGT2B3/UGT2B3(S316N), Sf-9 cells
were transfected with recombinant baculovirus for CYP3A1 and
UGT2B3/UGT2B3(S316N). The lanes labeled “UGT2B3” and
“UGT2B3(S316N)” show microsomal samples of single transfected cells. The
lanes labeled “UGT2B3+CYP3A1” and “UGT2B3(S316N)+CYP3A1” show
double transfected cells. Baculosomes (5 µg protein) from UGT2B3
single-expressing Sf-9 cells were electrophoresed (SDS-PAGE). For
baculosomes of CYP3A1-UGT2B3 co-expression systems, protein amounts
equivalent to UGT2B3 for the single-expressing system were used. Similarly,
baculosomes (3 µg protein) from UGT2B3(S316N) single-expressing Sf-9
cells were electrophoresed. For baculosomes of CYP3A1-UGT2B3(S316N)
co-expression systems, protein amounts equivalent to UGT2B3(S316N) for
the single-expressing system were used. Mock represents the baculosomes
(10 µg protein) from Sf-9 cells infected with baculovirus without passenger
DNA which served as controls. The proteins in the gel were electrically
transferred to a polyvinilidene difluoride membrane, and blotted with goat
anti-mouse low pI form UGT (A−C) and rabbit anti-CYP3A2 (D,E), antibodies,
respectively. In right panel of (A), baculosomes (25 µg protein) from
UGT2B3(S316N)-expressing Sf-9 cells were treated with Endoglycosidase H
(EndoH, 500 U) at 37◦C for 17 h. Four microgram protein of the digest was
subjected to immunoblotting with goat anti-mouse low pI form UGT antibody
as a primary antibody. Black and red arrow heads represent original and
deglycosylated UGT2B3(S316N), respectively.
profiles for both single and double expression could be
fitted to a Michaelis−Menten equation. When the 4-MU
concentration was varied, the Vmax was increased significantly
while the Km was comparable (Table 2). Both the Vmax and
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FIGURE 2 | Michaelis−Menten plots of 4-MU glucuronidation
catalyzed by UGT2B3 in the absence and presence of CYP3A1
co-expression. The plots of UGT2B3 single- and UGT2B3-CYP3A1-dual are
shown. The kinetics obtained by varying the 4-MU concentration (A) and
UDPGA concentration (B) are shown. In (A), the 4-MU concentration was
varied over the range 10−1000 µM while the UDPGA concentration was fixed
at 2 mM. In (B), the UDPGA concentration was varied over the range
50 µM–3 mM while the 4-MU concentration was fixed at 1 mM. The total
amount of protein added to the assay mixture was standardized at 100 µg.
For this, when necessary, control baculosomes were added to the reaction
mixture. Kinetic parameters were calculated by fitting the curve to a
Michaelis−Menten equation, and they are listed in Table 1.
Km of UGT2B3(S316N)-catalyzed 4-MU glucuronidation was
significantly increased by varying the UDPGA concentration
(Figure 3; Table 2). In sharp contrast to the wild-type
UGT2B3, co-expression of CYP3A1 increased UGT2B3(S316N)
activity.
Effect of EndoH-Treatment on the
Activity of UGT2B3(S316N)
The glucuronidation activities of microsomes expressing
UGT alone, UGT2B3(S316N), and UGT and CYP,
UGT2B3(S316N)-CYP3A1, were compared with or without
EndoH-treatment (Figure 4). The 4-MU glucuronidation
activity in UGT2B3(S316N)-CYP3A1 was significantly higher
than the UGT2B3(S316N) single expression even after treatment
with EndoH. The deglycosylation did not affect the activity of
UGT2B3(S316N).
TABLE 1 | Kinetic parameters for 4-MU glucuronide formation catalyzed
by Sf-9 microsomes expressing UGT2B3 alone and UGT2B3 + CYP3A1:
kinetics by varying 4-MU or UDPGA concentration.
Km (µM) Vmax
(pmol/min/mg
protein)
CLint
(µg/min/mg
protein)
By varying 4-MU concentration
UGT2B3 231 ± 31 682 ± 33 2.95
UGT2B3+CYP3A1 278 ± 20 377 ± 11∗ 1.36
By varying UDPGA concentration
UGT2B3 982 ± 70 664 ± 20 0.676
UGT2B3+CYP3A1 1088± 103 356 ± 14∗ 0.327
Data were fitted to a Michaelis−Menten equation (Figure 2). Results are the
estimated value ± SE. ∗Significantly different from UGT2B3 single expression
(p < 0.0001).
Protein−Protein Interaction of CYP3A1
and UGT2B3/UGT2B3(S316N)
(His)6-tagged CYP3A1 was constructed and, the baculovirus
encoding it subsequently co-transfected with either UGT2B3
or UGT2B3(S316N) which were tagged with HA. A band
immunoreactive to an anti-HA antibody was observed in the
precipitates (Figure 5). However, there was no pull down
when they were expressed singly. Therefore, both HA-tagged
UGT2B3 and UGT2B3(S316N) were pulled down by (His)6-
tagged CYP3A1 which suggests that CYP3A1 interacts with not
only UGT2B3 but also UGT2B3(S316N).
Prediction of the Structure of the
Carboxyl Terminal Domain of Wild-Type
UGT2B3 and a Glycosylated Mutant
UGT2B3(S316N)
The structures of part of the carboxyl terminal domain of
UGT2B3 and UGT2B3(S316N) were predicted by Phyre2 with
UGT2B7 as template (Figure 6). For comparison, the structure of
UGT2B3 which has Asn at 316 as a potential N-glycosylation site
was also predicted. For reference, the prediction was also carried
out for the UGT2B7 and UGT2B2 with UGT2B7 as a template.
In UGT2B7, Asn 315 is the corresponding residue. Overall, it
seems that the predicted structures are very similar to each
other. The structure around residue 316 or 315 (for UGT2B7), a
β-strand structure was observed except for UGT2B3. Although
the prediction does not include the effect of the glycosylation
chain, it is assumed that substitution of Ser 316 for Asn altered
the partial structure of UGT2B3.
DISCUSSION
The effect of CYP3A1 on UGT2B3 which lacks a potential
glycosylation site was studied. Since it is evident that CYP3A1
modulates UGT2B3 activity, N-glycosylation is not essential
for CYP3A1 to modulate this UGT. Furthermore, this study
demonstrates that the introduction of N-glycosylation to
UGT2B3 alters UGT sensitivity to a functional protein−protein
interaction with CYP3A: wild-type UGT2B3 which lacks
Frontiers in Pharmacology | www.frontiersin.org 5 November 2016 | Volume 7 | Article 427
fphar-07-00427 November 14, 2016 Time: 15:9 # 6
Nakamura et al. CYP3A1-Dependent Alteration of UGT2B3 Activity
FIGURE 3 | Michaelis−Menten plots of 4-MU glucuronidation
catalyzed by UGT2B3(S316N) in the absence and presence of CYP3A1
co-expression. The plots for UGT2B3(S316N) single- and
UGT2B3(S316N)-CYP3A1-dual are shown. The kinetics obtained by varying
the 4-MU concentration (A) and UDPGA concentration (B) are shown. In (A),
the 4-MU concentration was varied over the range 10−1000 µM while the
UDPGA concentration was fixed at 2 mM. In (B), the UDPGA concentration
was varied over the range 50 µM–7.5 mM while the 4-MU concentration was
fixed at 1 mM. The total amount of protein added to the assay mixture was
standardized at 100 µg. For this, when necessary, control baculosomes were
added to the reaction mixture. The kinetic parameters were calculated by
fitting the curve to a Michaelis−Menten equation, and they are listed in
Table 2.
N-glycosylation sites is suppressed by CYP3A1, whereas this
P450 increases UGT2B3(S316N) activity. These results suggest
that although the N-glycosylation of UGT is not essential for
modulation by CYP3A, the N-sugar chain linked to UGT is
one of the factors regulating this interaction between CYP3A
and UGT. In this study, we focused on the effect of CYP3A1
on UGT function. To allow a comparison, we carried out
several transfection experiments to obtain microsomes for UGT
single and CYP3A1-UGT dual microsomes with a comparable
UGT level and the results shown in Tables 1 and 2 allow
an examination of the effect of CYP3A1 on each UGT.
Although the activity of UGT2B3 and UGT2B3(S316N) cannot
be simply compared between Tables 1 and 2, it seems that
the introduction of N-glycosylation to UGT2B3 at this position
reduces the glucuronidation activity. Based on this, it is likely
that CYP3A1 increases the function of the glycosylated mutant
TABLE 2 | Kinetic parameters for 4-MU glucuronide formation catalyzed by
Sf-9 microsomes expressing UGT2B3(S316N) alone and UGT2B3(S316N) +
CYP3A1: kinetics by varying 4-MU or UDPGA concentration.
Km (µM) Vmax
(pmol/min/mg
protein)
CLint
(µg/min/mg
protein)
By varying 4-MU concentration
UGT2B3(S316N) 330 ± 33 143 ± 6 0.433
UGT2B3(S316N)+CYP3A1 444 ± 43 329 ± 43∗ 0.740
By varying UDPGA concentration
UGT2B3(S316N) 513 ± 51 142 ± 4 0.277
UGT2B3(S316N)+CYP3A1 1040 ± 100∗ 256 ± 8∗ 0.245
Data were fitted to a Michaelis−Menten equation (Figure 3). Results are
the estimated value ± SE. ∗Significantly different from UGT2B3(S316N) single
expression (p < 0.0001).
FIGURE 4 | Effect of EndoH-treatment on the glucuronidation
catalyzed by UGT2B3(S316N). Baculosomes (20 µg protein) from
UGT2B3(S316N) single- and UGT2B3(S316N)-CYP3A1 dual-expressing Sf-9
cells were treated with Endoglycosidase H (EndoH, 250 U) at 37◦C for 1 h.
The UGT activity was assayed with 100 or 1000 µM 4-MU and UDPGA fixed
at 3 mM. Significantly different from UGT2B3(S316N) single expression
(∗∗p < 0.001; ∗∗∗p < 0.0001).
UGT2B3(S316N) to approach that of the wild type. In general,
the methods that involve introduction of mutation(s) to the
potential glycosyation site to inhibit glycosylation are a well-
known strategy to investigate the role of glycosylation on enzyme
function. In some enzymes, the activity was increased by reducing
the glycosylation site, while in some other enzymes, the activity
was decreased (Skropeta, 2009). N-Glycosylation is involved in
the protein folding of UGT1A9 and important for catalytic
function (Nakajima et al., 2010). However, deglycosylation
of the mature UGT1A9 did not affect its function. In the
case of UGT2B3(S316N), N-glycosylation resulted in positive
modulation by CYP3A1 (Figure 4). However, the increase
in UGT activity was consistent even after EndoH-treatment
(Figure 4). Therefore, it is suggested that the engineered
glycosylated chain of UGT2B3(S316N) is no longer required after
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FIGURE 5 | Detection of an interaction between CYP3A1 and
UGT2B3/UGT2B3(S316N) by His-tag pull-down assay. UGT2B3-HA and
UGT2B3(S316N)-HA were expressed in the presence and absence of
coexpressed His-CYP3A1. The pull-down assay was performed according to
methods previously published (Miyauchi et al., 2015) with slight modification.
Microsomes (2 mg protein/mL) were solubilized with sodium cholate. Then the
solubilized microsomes were used in each assay. His-CYP3A1 and proteins
trapped by this P450 were eluted with buffer containing imidazole at a high
concentration. Each protein was detected by immunoblotting with a specific
antibody: rabbit anti-HA or rabbit anti-His. Solubilized microsomes and
His-CYP3A1–trapped samples are indicated as Input (30% of the input) and
PD (pull down), respectively. In (A), HA-tagged wild-type UGT2B3 (WT-HA)
was used. In (B), HA-tagged UGT2B3(S316N) (MT-HA) was used.
WT-HA+CYP-His and MT-HA+CYP-His indicate microsomes coexpressing
UGT2B3-HA or UGT2B3(S316N)-HA with His-CYP3A1, respectively.
Duplicate assays were carried out. For each pull-down sample, one half of the
precipitate was subjected to SDS-PAGE for detection with either HA or His
while the lanes shown by “C” represent a negative control sample obtained by
the same procedures but using solubilized control microsomes as an input,
with microsomes prepared from Sf-9 cells transfected with control baculovirus
alone. Details are described in the Section “Materials and Methods”.
maturation and fixing the conformation of UGT2B3(S316N).
This was also true for UGT2B3(S316N) without co-expression
of CYP3A1. Taken together, these findings suggest that the
complex formation with CYP3A1 affects the conformation
of UGT2B3(S316N). Although the kinetics were not studied
when examining the effect of deglycosylation, the activity was
consistent at both low and high substrate concentrations. It
FIGURE 6 | Comparison of the predicted structure of UGT2B3
wild-type, UGT2B3(S316N), UGT2B2, and UGT2B7: the region
spanning from 285 to 450. The models were constructed using the Phyre2
web server (Kelley et al., 2015) with the UGT2B7 (amino acid residue from
285 to 450) as a template. Template: UGT2B7, Miley et al. (2007) (DOI:
10.2210/pdb2o6l/pdb).
is assumed that deglycosylation did not alter the affinity to
the substrate. Since glycosylation of UGT has been shown
to be important during synthesis of the enzyme but not
once the mature enzyme is formed (Nakajima et al., 2010),
it is assumed that the CYP3A1-dependent modulation of
UGT2B3(S316N) that we observed is due to the interaction
of CYP3A4 with the secondary structure of UGT2B3(S316N)
during the process of formation of the mature UGT enzyme.
However, whether glycosylation or merely the presence of the
Asn at that site is sufficient to alter structure and function,
remains to be clarified in a future study. Nevertheless, our
current study suggests that the introduction of a potential
glycosylation site to UGT2B3 alters its CYP3A1-dependent
modulation.
UGT2B7 is known to interact with CYP3A4 (Takeda et al.,
2005, 2009; Miyauchi et al., 2015). Furthermore, the crystal
structure of the cofactor-binding domain of UGT2B7 (from
residues 285 to 450) has been determined (Miley et al., 2007). So
far, that is the sole example of a crystal structure of mammalian
UGTs. Concerning the structural differences between UGT2B3
and UGT2B3(S316N), the structures of the corresponding region
were predicted by Phyre2 with UGT2B7 as a template (Figure 6).
The results were very similar except around the 316th residue.
So, on the basis of the prediction, the substitution of Ser at
the 316th residue of UGT2B3 by Asn converted the random
coil to a β-strand structure (Figure 6). It is reasonable to
suppose that the combination of the structural difference and
the N-glycosylation in UGT2B3(S316N) resulted in a different
susceptibility to modulation by CYP3A1.
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This study suggests that N-glycosylation of UGT is one of the
determinants of the functional interaction between CYP3A and
UGT. UGT function is known to be affected by N-glycosylation
(Mackenzie, 1990a,b; Barbier et al., 2000; Nakajima et al., 2010;
Nagaoka et al., 2012). Many UGTs have N-glycosylation at
more than two positions (Barbier et al., 2000; Nagaoka et al.,
2012). Therefore, the role of N-glycosylation of the other UGTs
is very important for functional protein−protein interactions
with CYP3A. Further studies are necessary to determine the
importance of N-glycosylation of UGTs in the UGT-CYP
interactions.
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